



# Medical Coverage Policy

Effective Date..... 6/15/2023  
Next Review Date..... 6/15/2024  
Coverage Policy Number ..... 0142

## Ultrasound in Pregnancy (including 3D, 4D and 5D Ultrasound)

### Table of Contents

Overview.....	1
Coverage Policy.....	1
General Background.....	2
Medicare Coverage Determinations.....	7
Coding Information.....	7
References.....	8

### Related Coverage Resources

[Fetal Surgery](#)  
[Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis](#)

#### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

### Overview

This Coverage Policy addresses obstetric ultrasound use in pregnancy.

### Coverage Policy

Up to two (2) routine two-dimensional (2D) standard or limited obstetrical ultrasound examinations (CPT® codes 76801, 76805, 76811, 76815) are considered medically necessary.

A specialized obstetrical ultrasound (CPT® code 76816) is considered medically necessary when performed to follow up specific medical indications/complications.

An obstetrical ultrasound examination performed solely to determine gender or to provide photographic representation of the fetus is considered not medically necessary for the management of a pregnancy.

**Three-dimensional (3D), four-dimensional (4D) or five dimensional (5D) obstetrical ultrasonography is considered experimental, investigational or unproven.**

## General Background

Ultrasound imaging uses high-frequency sound waves to produce dynamic images of organs, tissues or blood-flow inside the body. The procedure involves the use of a transducer, which sends a stream of high-frequency sound waves into the body and detects their echoes as they bounce off internal structures. The sound waves are converted to electrical impulses, which are processed to form an image displayed on a computer monitor. Obstetricians use ultrasounds at a very low power level to check fetal size, location, age and quantity. Ultrasound is also used in this manner to assess for the presence of some types of birth defects, fetal movement, breathing and heartbeat.

Two-dimensional (2D) ultrasound is considered standard or conventional ultrasound. In conventional 2D scanning the ultrasound image is made up of a series of thin slices and only one slice can be seen at any one time. For three-dimensional (3D) ultrasonography a volume of echoes is taken, which can be stored digitally and shaded to produce life-like pictures of the fetus. It is possible to measure distance, area and volume from volume data with 3D ultrasound. Three-dimensional ultrasound data can be sliced in any orientation, allowing for any diameter or cross-sectional area of the organ to be measured. Four-dimensional ultrasound adds motion to the 3D imaging display. This feature typically involves 3D multiplanar imaging that is acquired at rates that stimulate movement such as heart motion or fetal activity. With 4D ultrasound, the life-like fetal pictures can be seen to move in real time so the activity of the baby inside the womb can be studied. Five-dimensional (5D) ultrasound reconstructs conventional 2D images from 3D ultrasound volume data, automating the process of acquiring diagnostic images through the use of a software package. The ultrasound system WS80A (Samsung Medison Co, Ltd, Seoul, Korea) includes several software packages focusing on specific areas including fetal brain and heart structure, nuchal translucency and fetal biometry.

There is no consensus on the best use of ultrasonography in screening for abnormal pregnancies in low-risk populations. Routine ultrasound has also not been shown to improve outcomes in low-risk pregnancies. However, many health care providers recommend that one ultrasound examination, usually done between 18 and 20 weeks of pregnancy, be included as a routine part of prenatal care. The use of ultrasonography to assess for potential fetal abnormalities, confirm the site of pregnancy within the uterus, and determine gestational age is considered the standard of care. Also, the use of ultrasound scanning during the first trimester is correlated with reduced post-term labor induction rates as compared to second trimester ultrasound scanning (American College of Obstetricians and Gynecologists [ACOG], 2014; Reaffirmed 2020).

ACOG uses the following terms to describe various types of ultrasound examinations performed during the second and third trimesters (ACOG, 2016; Reaffirmed 2022):

- Standard: includes an evaluation of fetal presentation amniotic fluid volume, cardiac activity, placental position, fetal biometry and an anatomic survey.
- Limited: performed when a specific question requires investigation; appropriate only when the patient has had a prior complete examination.
- Specialized: performed when an anomaly is suspected on the basis of history, biochemical abnormalities or clinical evaluation, or when results from either a limited or standard ultrasound examination are suspicious.

### First Trimester Ultrasound Examination

A first trimester ultrasound examination is performed prior to 14 0/7 weeks of gestation for a number of indications which include the following (ACOG, 2016; Reaffirmed 2022):

- confirmation of the presence of an intrauterine pregnancy
- evaluation of a suspected ectopic pregnancy
- evaluation of vaginal bleeding
- evaluation of pelvic pain

- to estimate gestational age
- to diagnosis or evaluate multiple gestations
- to confirm cardiac activity
- as adjunct to chorionic villus sampling, embryo transfer, or localization and removal of an intrauterine device
- assessment of certain fetal anomalies, such as anencephaly, in patients at high risk
- evaluation of maternal pelvic or adnexal masses or uterine abnormalities
- screening for fetal aneuploidy
- evaluation of suspected gestational trophoblastic disease (e.g., hydatidiform mole)

First trimester crown-rump measurement via ultrasound is the most accurate means for dating of pregnancy (ACOG, 2016; Reaffirmed 2022). Obtaining an accurate expected date of delivery (EDD) using ultrasonography early in the pregnancy can reduce the incidence of pregnancies diagnosed as post-term and minimize unnecessary interventions. The premise is that the EDD as calculated by menstrual age is often inaccurate and therefore can be the basis for presumed but incorrect diagnosis of post-term pregnancy. The reported frequency of post-term pregnancy is approximately 7%, with most cases of resulting from a prolongation of gestation. Other cases result from an inability to accurately define EDD. The risk of adverse sequelae may be reduced by making an accurate assessment of gestational age and diagnosis of post-term gestation, as well as recognition and management of risk factors. Although detection of some anomalies is possible as early as 11–14 weeks, the use of ultrasonography to screen for major fetal anomalies in the first trimester should not replace the more appropriate screening of fetal anatomy in the second trimester (Wax, et al., 2015).

### **Second and Third Trimester Ultrasound Examination**

Kaelin Agten et al. (2021) conducted a Cochrane review that assessed the effectiveness of a routine pregnancy ultrasound before 24 weeks compared to selective or no ultrasound examination on the early diagnosis of abnormal pregnancy location, termination for fetal congenital abnormality, multiple pregnancy, maternal outcomes and later fetal compromise.

The review included 13 randomized controlled trials with 85,265 participants and four comparisons:

- First trimester routine versus selective ultrasound (n=4 studies/1791 women)
- Second trimester routine versus selective ultrasound (n=7 studies/36,053 women)
- Standard care plus two ultrasounds and referral for complications versus standard care (n=1 study/47,431 women)
- Ultrasound results communicated to both patient and doctor versus concealed ultrasound results (blinded to both patient and doctor at any time before 24 weeks) (n=1 study/1095 women)

The authors concluded the early scans may reduce short term maternal anxiety and later scans may reduce labor induction for post-maturity. Additionally, ultrasounds may improve detection of major fetal abnormalities and reduce the number of undetected twin pregnancies. Neither type of scan appeared to change other important maternal or fetal outcomes, but the review may underestimate the effect because trials were mostly from relatively early in the development of the technology, and many control participants also had scans. The trials were also underpowered to show an effect on other important maternal or fetal outcomes.

Ultrasonography can be beneficial in many situations in the second and third trimesters. Indications for ultrasound examination in the second- (14 0/7 weeks–27 6/7 weeks) and third- (28 0/7 weeks–40 6/7 weeks) trimester include the following (ACOG, 2016; Reaffirmed 2022):

- estimation of gestational age
- evaluation of fetal growth
- evaluation of vaginal bleeding
- evaluation of cervical insufficiency
- evaluation of abdominal and pelvic pain
- determination of fetal presentation
- evaluation of suspected multiple gestation

- adjunct to amniocentesis or other procedure
- significant discrepancy between uterine size and clinical dates
- evaluation of pelvic mass
- examination of suspected gestational trophoblastic disease (e.g., hydatidiform mole)
- adjunct to cervical cerclage placement
- evaluation of suspected ectopic pregnancy
- evaluation of suspected fetal death
- evaluation of suspected uterine abnormality
- evaluation for fetal well-being
- evaluation of suspected amniotic fluid abnormalities
- evaluation of suspected placental abruption
- adjunct to external cephalic version
- evaluation for premature rupture of membranes or premature labor
- evaluation for abnormal biochemical markers
- follow-up evaluation of a fetal anomaly
- follow-up evaluation of placental location for suspected placenta previa
- evaluation for those with a history of previous congenital anomaly
- evaluation of fetal condition in late registrants for prenatal care
- to assess findings that may increase the risk of aneuploidy
- to screen for fetal anomalies

In addition, cervical length screening during the second trimester is a tool that can be utilized to identify women at increased risk for preterm birth. Cervical shortening is one of the first steps in the processes leading to labor and can occur several weeks prior to labor (Berghella, 2023). A short cervix, defined as a transvaginal sonographic cervical length  $\leq 25$  mm in the mid-trimester of pregnancy, is a significant risk factor for spontaneous preterm birth, with a high predictive accuracy for spontaneous preterm birth  $< 34$  weeks of gestation and a moderate to low predictive accuracy for spontaneous preterm birth  $< 37$  weeks of gestation. Identification of women with a short cervix and treatment with vaginal progesterone can reduce the frequency of preterm birth. Several authors have proposed that universal mid-trimester transvaginal cervical length screening for women with a singleton gestation, followed by treatment with vaginal progesterone for those with a short cervix, meets all of the World Health Organization criteria for endorsing the implementation of a screening test in clinical medicine (Romero, et al., 2018).

#### **Use of 2D Compared to 3D, 4D and 5D Ultrasound**

The ultimate impact of 3D and 4D ultrasound as new diagnostic imaging technologies is difficult to characterize due to the rapidly changing technological advances in the medical imaging industry. Potential areas of promise include fetal facial anomalies, neural tube defects, and skeletal malformations where 3D ultrasonography may be helpful in diagnosis as an adjunct to, but not a replacement for, 2D ultrasonography (ACOG, 2016; Reaffirmed 2022). 3D ultrasound may provide additional diagnostic information, however there is a lack of data demonstrating the impact on clinical outcomes. Proponents of the use 4D ultrasound suggest that the real-time movements of the fetus obtained improves maternal bonding, however the impact of 4D ultrasound scanning on the diagnosis and management of fetal abnormalities has also not been demonstrated.

**U.S. Food and Drug Administration (FDA):** A number of ultrasound devices and probes have received FDA approval. The FDA notes that these devices are considered prescription devices and are to be used only with a physician's order. Fetal ultrasound imaging provides real-time images of the fetus. Ultrasound use for fetal scanning is generally considered safe if properly used when information is required about a pregnancy. However, ultrasound is a form of energy and even at low levels, some studies have shown that it can produce physical effects in tissue, such as jarring vibrations and rise in temperature. Although there is a lack of evidence of any harm to the fetus due to ultrasound imaging, prudent use by a trained health care provider is important. The FDA strongly discourages using 3D and 4D ultrasound devices for creating fetal keepsake images and videos (U.S. Food and Drug Administration [FDA], 2014).

**Literature Review:** The use of 3D and 4D ultrasound has been evaluated in randomized controlled trials (RCTs) and observational studies. A cross-sectional study by Espinoza et al. (2010) assessed the effectiveness of 4D

ultrasound for fetal echocardiography. A total of seven international centers uploaded nonconsecutive 4D volume data sets (n=120). Diagnostic indices of 4D ultrasound in the identification of fetuses with congenital heart defects were calculated. Overall, the median (range) sensitivity and specificity were 93% (77%–100%), 96% (84%–100%) respectively, with a positive predictive value (PPV) of 96% (83%–100%), and a negative predictive value (NPV) of 93% (79%–100%). False-positive and negative rates were 4.8% (2.7%–25%), and 6.8% (5%–22%), respectively.

A prospective study (n=118) by Chen et al. (2009) assessed the reproducibility of measurements of nasal bone length using a three-dimensional (3D) ultrasound in the first trimester compared to 2D measurements. The successful rate of measurement of nasal bone length by 3D ultrasound was 79.7%. There was significant inter-method difference between the results obtained by 2D and 3D, substantial variation between observers in 3D measurement of fetal nasal bone length in the first trimester. Independent 3D measurement of nasal bone was found to have no additional advantages over 2D sonography.

A prospective randomized controlled study (n=60) by Lapaire et al. (2007) assessed the impact of 3D versus 2D ultrasound on maternal-fetal bonding. Maternal recognition was higher with 3-D US (p=0.004), however the maternal preference of 3D US had no significant impact on maternal-fetal bonding. Another randomized study (n=100) by Rustico et al., (2005) reported that the addition of 4D ultrasound results did not significantly change the perception that women have of their baby nor their antenatal emotional attachment compared with conventional 2D ultrasound.

Randomized controlled and evaluation studies (n=range of 63–3472) comparing the diagnostic accuracy of the different ultrasonographic techniques for various indications have found the diagnostic information provided by 3D/4D ultrasound to be consistent with that provided by 2D ultrasound and have reported that 3D ultrasound is most helpful as an adjunct to 2D ultrasound imaging (Goetzinger, et al., 2018; Hsu, et al., 2013; Rizzo, et al., 2011; Kurjak, et al., 2010; Goncalves, et al., 2006; Merz and Welter, 2005).

Evidence evaluating 5D ultrasonography is primarily in the form of prospective comparative studies with patient populations ranging from 39–183. The results of the studies suggest that 5D ultrasonography is faster, requires less expertise to interpret, and is comparable to 2D in accuracy. However, there is a lack of data to support that any additional benefit or improved outcomes are achieved when using 5D ultrasounds over conventional 2D ultrasounds (Laban, et al., 2018; Rizzo, et al., Oct 2016; Rizzo, et al., Jul 2016; Hur, et al., 2015).

Although 3D/4D/5D ultrasonography can produce more detailed and recognizable images than conventional 2D ultrasound, the clinical utility of this remains unclear. Additional well designed studies are needed to clearly define the role of 3D/4D/5D in obstetrics as well as to establish appropriate applications for this method of imaging.

### **Professional Societies/Organizations**

**American College of Obstetricians and Gynecologists (ACOG)/American Institute of Ultrasound in Medicine (AIUM):** A 2016 clinical management guideline on the use of ultrasound in pregnancy issued by ACOG and AIUM stated that the best gestational age for an obstetric ultrasound will depend on the clinical indication for the examination. First trimester ultrasonography is most accurate for patients with uncertain or unreliable menstrual dating or with an indication to confirm viability. When used as part of combined first-trimester screening or integrated screening for aneuploidy, an ultrasound examination with nuchal translucency measurement before 14 0/7 weeks of gestation provides accurate dating of pregnancy and an effective screening test for trisomy 13, trisomy 18, and trisomy 21 when combined with maternal age and serum markers. ACOG stated that in the absence of other specific indications, the optimal time for a single ultrasound examination is at 18–22 weeks of gestation. This timing allows for a survey of fetal anatomy in most women and an accurate estimation of gestational age (ACOG, 2016; Reaffirmed 2022).

According to the joint guidelines, the technical advantages of 3D ultrasonography include its ability to acquire and manipulate an infinite number of planes and to display ultrasound planes traditionally inaccessible by 2D ultrasonography. Despite these technical advantages, proof of a clinical advantage of 3D ultrasonography in prenatal diagnosis in general is still lacking. Until clinical evidence shows a clear advantage to conventional 2D

ultrasonography, 3D ultrasonography is not considered a required modality at this time (ACOG, 2016; Reaffirmed 2022).

**American Institute of Ultrasound in Medicine (AIUM)/American College of Radiology (ACR)/American College of Obstetricians and Gynecologists (ACOG)/Society for Maternal-Fetal Medicine (SMFM)/Society of Radiologists in Ultrasound (SRU):** The 2018 AIUM-ACR-ACOG-SMFM-SRU practice parameter for the performance of standard diagnostic obstetric ultrasound examinations stated that obstetric ultrasound examinations should only be performed when there is a valid medical reason, and the lowest possible ultrasonic exposure settings should be used. The practice parameter described the key elements of standard ultrasound examinations in the first, second, and third trimesters of pregnancy. A standard obstetric ultrasound examination in the first trimester should consist of an evaluation of the presence, size, location, and number of gestational sacs. The second or third trimester ultrasound can include an evaluation of the fetal number, cardiac activity, presentation, amniotic fluid volume, placental position, fetal biometry, and an anatomic survey. In some cases, it may be necessary to perform a more detailed fetal anatomic examination, such as when an abnormality is found or suspected on the standard examination or in pregnancies at high risk for fetal anomalies.

### **Use Outside of the US**

The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) is a scientific organization that encourages safe clinical practice and high-quality teaching and research related to diagnostic imaging in women's healthcare. In 2022 the ISUOG published updated practice guidelines on the performance of a routine mid-trimester fetal ultrasound. ISUOG recommended a mid-trimester ultrasound as part of routine pregnancy care for all pregnant individuals. In some settings, a routine first-trimester ultrasound may have already been done. The guidelines stated that if the first-trimester ultrasound is normal, a standard mid-trimester ultrasound should still be offered. Regarding three-dimensional (3D) and four-dimensional (4D) ultrasound the ISUOG stated that these modalities are not currently used for routine first-trimester fetal anatomical evaluation. Three-dimensional ultrasound may be useful in the second trimester for examination of the fetal face, however this is not part of the routine evaluation. ISUOG, et al., 2023; Salomon, et al., 2022).

The World Health Organization (WHO) published an update to the maternal and fetal assessment: imaging ultrasound before 24 weeks of pregnancy in the antenatal care recommendations for a positive pregnancy experience. The WHO stated that "one ultrasound scan before 24 weeks of gestation (early ultrasound) is recommended for pregnant women to estimate gestational age, improve detection of fetal anomalies and multiple pregnancies, reduce induction of labor for post-term pregnancy, and improve a woman's pregnancy experience" (WHO, 2022).

The Canadian Agency for Drugs and Technologies in Health (CADTH) Technology Assessment on Obstetrical Ultrasound During Pregnancy published a Rapid Response Report in 2021. The technology assessment reviewed the available evidence on the safety of routine versus more frequent use of obstetrical ultrasound among individuals who are pregnant as well as reviewed the evidenced based guidelines on the use of obstetrical ultrasound during pregnancy. There was not any relevant evidence identified comparing the safety of frequent obstetrical ultrasounds during pregnancy to the routine use of obstetrical ultrasound during pregnancy; therefore, no summary can be provided. The report identified 10 evidence-based guidelines that provided recommendations regarding various clinical indications for obstetrical ultrasound, as well as for the frequency of obstetrical ultrasound during pregnancy. However, due to the limited evidence of these guidelines, the recommendations should be interpreted with caution. One guideline recommended against obstetrical ultrasound for non-medical purposes and recommended that ultrasound exposure be as low as reasonably possible during pregnancy. Lastly, the guidelines recommend that there are specific patient populations for whom more frequent obstetrical ultrasound examinations may be required. These populations included pregnancies affected by certain congenital infections, people pregnant with twins, pregnant adolescents, and pregnant people at high risk for fetal anomalies or for whom midtrimester transabdominal ultrasound would be challenging (CADTH, 2021).

The National Institute for Health and Clinical Excellence (NICE) guideline on antenatal care addressed the routine care that pregnant women and their babies should receive. The guideline recommended that women should be offered an ultrasound between 11+2 weeks and 14+1 weeks for determining gestational age, multiple pregnancy and possible fetal anomaly screening. An additional ultrasound should be offered to screen for fetal anomalies and to determine placental location between 18+0 weeks and 20+6 weeks. Additionally, if there are

concerns regarding fundal height, unexplained vaginal bleeding, or a breech presentation an ultrasound may be considered. The guideline further stated that routine use of ultrasound scanning for uncomplicated singleton pregnancies after 284 weeks of gestation is not supported by the evidence and therefore should not be offered (NICE, 2021).

The Society of Obstetricians and Gynaecologists of Canada (SOGC) guideline on the use of first trimester ultrasounds stated that a first trimester ultrasound is indicated for assessment of threatened abortion to document fetal viability, for incomplete abortion to identify retained products of conception and prior to pregnancy termination. Additionally, it can be used to identify multiple gestations, used during diagnostic or therapeutic procedures requiring visual guidance and to establish early fetal genetic and anatomic screening (e.g., ectopic pregnancy, molar pregnancy, and suspected pelvic masses). First trimester ultrasound is not recommended to diagnose pregnancy but is recommended to date a pregnancy. If menstrual dating is reliable and an early comprehensive pregnancy ultrasound (11–14 weeks) is planned, dating should be confirmed concurrently with this exam (Van den Hof, et al., 2019).

## Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD	National	Ultrasound Diagnostic Procedures (220.5)	9/28/2007

Note: Please review the current Medicare Policy for the most up-to-date information.  
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

## Coding Information

- Note:** 1) This list of codes may not be all-inclusive.  
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when used to report up to two (2) routine two-dimensional (2D) standard or limited obstetrical ultrasound examinations:**

CPT®* Codes	Description
76801	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (<14 weeks 0 days), transabdominal approach; single or first gestation
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation
76815	Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses

**Considered Medically Necessary when used to report a specialized obstetrical ultrasound used to follow up specific medical indications/complications:**

CPT®* Codes	Description
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg., re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus

**Considered Experimental/Investigational/Unproven when used to report three-dimensional (3D), four-dimensional (4D) or five-dimensional (5D) obstetrical ultrasonography:**

CPT®* Codes	Description
76376	3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound or other tomographic modality with image postprocessing under concurrent supervision; not requiring image postprocessing on an independent workstation.
76377	3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation.
76499	Unlisted diagnostic radiographic procedure

**\*Current Procedural Terminology (CPT®) ©2022 American Medical Association: Chicago, IL.**

## References

1. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins—Obstetrics. Practice bulletin No. 146: Management of late-term and postterm pregnancies. *Obstet Gynecol.* 2014 Aug;124(2 Pt 1):390-6. Reaffirmed 2020.
2. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins—Obstetrics and the American Institute of Ultrasound in Medicine. Practice Bulletin No. 175: Ultrasound in Pregnancy. *Obstet Gynecol.* 2016 Dec;128(6):e241-e256. Reaffirmed 2022.
3. American Institute of Ultrasound in Medicine (AIUM) Practice Parameter for the Performance of Detailed Second- and Third-Trimester Diagnostic Obstetric Ultrasound Examinations. *J Ultrasound Med.* 2019 Dec;38(12):3093-3100.
4. American Institute of Ultrasound in Medicine (AIUM)-American College of Radiology (ACR)-American College of Obstetricians and Gynecologists (ACOG)-Society for Maternal-Fetal Medicine (SMFM)-Society of Radiologists in Ultrasound (SRU) Practice Parameter for the Performance of Standard Diagnostic Obstetric Ultrasound Examinations. *J Ultrasound Med.* 2018 Nov;37(11):E13-E24.
5. Berghella V. Short cervix before 24 weeks: Screening and management in singleton pregnancies. In: *UpToDate*, Simpson LL, Levine D (Eds), UpToDate, Waltham, MA. Literature review current through March 2023. Last updated January 9, 2023. Accessed April 11, 2023.
6. Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH Health Technology Review. *Obstetrical Ultrasound During Pregnancy.* Issue 12. December 2021. Accessed April 11, 2023. Available at URL address: <https://cadth.ca/obstetrical-ultrasound-during-pregnancy>
7. Centers for Medicare and Medicaid Services (CMS). National Coverage Determinations (NCDs) alphabetical index. Accessed April 11, 2023. Available at URL address: <https://www.cms.gov/medicare-coverage-database/indexes/ncd-alphabetical-index.aspx>
8. Chen M, Wang HF, Leung TY, Fung TY, Chan LW, Sahota DS, et al. First trimester measurements of nasal bone length using three-dimensional ultrasound. *Prenat Diagn.* 2009 Aug;29(8):766-70.
9. Espinoza J, Lee W, Comstock C, Romero R, Yeo L, Rizzo G, et al. Collaborative study on 4-dimensional echocardiography for the diagnosis of fetal heart defects: the COFEHD study. *J Ultrasound Med.* 2010 Nov;29(11):1573-80.
10. Goetzinger KR, Cahill AG, Odibo L, Macones GA, Odibo AO. Three-dimensional power doppler evaluation of cerebral vascular blood flow: A novel tool in the assessment of fetal growth restriction. *J Ultrasound Med.* 2018; 37(1):139-147.



11. Goncalves LF, Lee W, Espinoza J, Romero R. Three- and 4-dimensional ultrasound in obstetric practice: does it help? *J Ultrasound Med.* 2005 Dec;24(12):1599-624.
12. Goncalves LF, Nien JK, Espinoza J, Kusanovic JP, Lee W, Swope B, et al. What does 2-dimensional imaging add to 3- and 4-dimensional obstetric ultrasonography? *J Ultrasound Med.* 2006 Jun;25(6):691-9.
13. Hsu JC, Wu YC, Wang PH, Wang H, Juang CM, Chen YJ, et al. Quantitative analysis of normal fetal brain volume and flow by three-dimensional power Doppler ultrasound. *J Chin Med Assoc.* 2013 Sep;76(9):504-9.
14. Hur H, Kim YH, Cho HY, Park YW, Won HS, Lee MY, et al. Feasibility of three-dimensional reconstruction and automated measurement of fetal long bones using 5D Long Bone. *Obstet Gynecol Sci.* 2015; 58(4):268-276.
15. International Society of Ultrasound in Obstetrics and Gynecology; Bilardo CM, Chaoui R, Hyett JA, Kagan KO, Karim JN, Papageorghiou AT, Poon LC, Salomon LJ, Syngelaki A, Nicolaides KH. ISUOG Practice Guidelines (updated): performance of 11-14-week ultrasound scan. *Ultrasound Obstet Gynecol.* 2023 Jan;61(1):127-143.
16. Kaelin Agten A, Xia J, Servante JA, Thornton JG, Jones NW. Routine ultrasound for fetal assessment before 24 weeks' gestation. *Cochrane Database Syst Rev.* 2021 Aug 26;8(8):CD014698.
17. Kurjak A, Abo-Yaqoub S, Stanojevic M, Yigiter AB, Vasilj O, Lebit D, et al. The potential of 4D sonography in the assessment of fetal neurobehavior--multicentric study in high-risk pregnancies. *J Perinat Med.* 2010;38(1):77-82.
18. Laban M, Alanwar AA, Etman MK, Elsokkary MS, Elkotb AM, Hasanien AS, et al. Five-dimensional long bones biometry for estimation of femur length and fetal weight at term compared to two-dimensional ultrasound: a pilot study. *J Matern Fetal Neonatal Med.* 2018 Aug;31(15):2036-2042.
19. Lapaire O, Alder J, Peukert R, Holzgreve W, Tercanli S. Two- versus three-dimensional ultrasound in the second and third trimester of pregnancy: impact on recognition and maternal-fetal bonding. A prospective pilot study. *Arch Gynecol Obstet.* 2007 Nov;276(5):475-9.
20. Merz E, Welter C. 2D and 3D Ultrasound in the evaluation of normal and abnormal fetal anatomy in the second and third trimesters in a level III center. *Ultraschall Med.* 2005 Feb;26(1):9-16.
21. Moncrieff G, Finlayson K, Cordey S, McCrimmon R, Harris C, Barreix M, et al. First and second trimester ultrasound in pregnancy: A systematic review and metasynthesis of the views and experiences of pregnant women, partners, and health workers. *PLoS One.* 2021 Dec 14;16(12):e0261096.
22. National Institute for Health and Clinical Excellence (NICE). NICE clinical guideline 201. Antenatal care. August 2021. Accessed April 11, 2023. Available at URL address: <https://www.nice.org.uk/guidance/ng201>
23. Rizzo G, Abuhamad AZ, Benacerraf BR, Chaoui R, Corral E, Addario VD, et al. Collaborative study on 3-dimensional sonography for the prenatal diagnosis of central nervous system defects. *J Ultrasound Med.* 2011 Jul;30(7):1003-8.
24. Rizzo G, Aiello E, Pietrolucci ME, Arduini D. The feasibility of using 5D CNS software in obtaining standard fetal head measurements from volumes acquired by three-dimensional ultrasonography: comparison with two-dimensional ultrasound. *J Matern Fetal Neonatal Med.* 2016 Jul;29(14):2217-22

25. Rizzo G, Capponi A, Persico N, Ghi T, Nazzaro G, Boito S, et al. 5D CNS+ software for automatically imaging axial, sagittal, and coronal planes of normal and abnormal second-trimester fetal brains. *J Ultrasound Med*. 2016 Oct;35(10):2263-72.
26. Romero R, Conde-Agudelo A, Da Fonseca E, O'Brien JM, Cetingoz E, Creasy GW, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. *Am J Obstet Gynecol*. 2018 Feb;218(2):161-180.
27. Rustico MA, Mastromatteo C, Grigio M, Maggioni C, Gregori D, Nicolini U. Two-dimensional vs. two- plus four-dimensional ultrasound in pregnancy and the effect on maternal emotional status: a randomized study. *Ultrasound Obstet Gynecol*. 2005 May;25(5):468-72.
28. Salomon LJ, Alfirevic Z, Berghella V, Bilardo CM, Chalouhi GE, Da Silva Costa F, et al. ISUOG Practice Guidelines (updated): performance of the routine mid-trimester fetal ultrasound scan. *Ultrasound Obstet Gynecol*. 2022 Jun;59(6):840-856. Erratum in: *Ultrasound Obstet Gynecol*. 2022 Oct;60(4):591.
29. Shanker SA, Coleman B, Timor-Tritsch IE, Bhide A, Bromley B, Cahill AG, et al. Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum Ultrasound Marker Task Force: Consensus on definition of markers and approach to the ultrasound examination in pregnancies at risk for placenta accreta spectrum. *Am J Obstet Gynecol*. 2021 Jan;224(1):B2-B14. Erratum in: *Am J Obstet Gynecol*. 2021 Jul;225(1):91.
30. Smith GC, Moraitis AA, Wastlund D, Thornton JG, Papageorghiou A, Sanders J, et al. Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis. *Health Technol Assess*. 2021 Feb;25(15):1-190.
31. U.S. Food and Drug Administration, FDA Consumer Health Information. Avoid Fetal "Keepsake" Images, Heartbeat Monitors. December 2014. Accessed April 11, 2023. Available at URL address: <https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm095508.htm>
32. U.S. Food and Drug Administration, Medical Imaging. Radiation Emitting Products and Procedures. Ultrasound Imaging. September 2020. Accessed April 11, 2023. Available at URL address: <https://www.fda.gov/Radiation-EmittingProducts/RadiationEmittingProductsandProcedures/MedicalImaging/ucm115357.htm>
33. Van den Hof MC, Smithies M, Nevo O, Oullet A. No. 375-Clinical Practice Guideline on the Use of First Trimester Ultrasound. *J Obstet Gynaecol Can*. 2019 Mar;41(3):388-395.
34. Wax J, Minkoff H, Johnson A, Coleman B, Levine D, Helfgott A, et al. Consensus report on the detailed fetal anatomic ultrasound examination: indications, components, and qualifications. *J Ultrasound Med*. 2014 Feb;33(2):189-95.
35. Wax JR, Benacerraf BR, Copel J, O'Keeffe D, Riley L, Minkoff H, et al. Consensus Report on the 76811 Scan: Modification. *J Ultrasound Med*. 2015 Oct;34(10):1915.
36. WHO antenatal care recommendations for a positive pregnancy experience: Maternal and fetal assessment update: imaging ultrasound before 24 weeks of pregnancy [Internet]. Geneva: World Health Organization; 2022.

---

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna.